Rallybio is a privately-held early-stage biotechnology company incorporated in January 2018.  Our ambition is to create a world-leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development.  We will work on highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies.

Rallybio’s founders are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience.  The Company is based in Farmington, CT, at the University of Connecticut’s Technology Incubation Program.  We are assembling a small team of people with an outstanding track record in pharmaceutical research and development to search for and evaluate assets using a series of robust clinical and commercial filters that will allow us to identify and acquire a portfolio of high-quality small molecule and protein-based assets in the late discovery to early clinical stages of drug development.

We have secured $37.0 million in Series A funding with lead financing from 5AM Ventures, Canaan Partners, and New Leaf Venture Partners, and additional public-sector participation from Connecticut Innovations.